PMID- 33340056
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20220501
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 81
IP  - 1
DP  - 2022 Feb
TI  - Janus kinase inhibitors for treating active ankylosing spondylitis: 
      a meta-analysis of randomized controlled trials.
PG  - 71-76
LID - 10.1007/s00393-020-00948-3 [doi]
AB  - OBJECTIVE: In this study, we aimed to assess the safety and efficacy of Janus 
      kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS). METHODS: We 
      conducted a Bayesian network meta-analysis using direct and indirect data from 
      randomized controlled trials (RCTs), and examined the safety and efficacy of JAK 
      inhibitors in active AS patients exhibiting inadequate response or intolerance to 
      two or more non-steroidal anti-inflammatory drugs (NSAIDs). RESULTS: RCTs 
      included a total of 406 patients (203 experimental subjects and 203 controls) 
      from three studies on upadacitinib, filgotinib, and tofacitinib. Assessment of 
      SpondyloArthritis International Society 20% improvement (ASAS20), ASAS40, and 
      ASAS5/6 responses were significantly higher in the JAK inhibitor group than in 
      the placebo group. Other efficacy outcomes, such as ASAS partial remission, Bath 
      Ankylosing Spondylitis Disease Activity Index (BASDAI50), Ankylosing Spondylitis 
      Disease Activity Score (ASDAS), Spondyloarthritis Research Consortium of Canada 
      (SPARCC) Magnetic Resonance Imaging (MRI) scores, and Bath Ankylosing Spondylitis 
      Functional Index (BASFI) were also significantly higher in the JAK inhibitor 
      group compared to the placebo group. The JAK inhibitors significantly improved 
      disease activity (ASAS partial remission, BASDAI50, ASDAS), function (BASFI), and 
      MRI outcomes (SPARCC MRI spine). However, the incidence of adverse events (AEs) 
      and serious adverse events (SAEs), and the rate of withdrawal attributed to AEs 
      did not differ between the JAK inhibitor and placebo groups. CONCLUSION: JAK 
      inhibitors were effective in active AS patients exhibiting an inadequate response 
      or intolerance to two or more NSAIDs, without the risk of SAEs; this suggests 
      that based on our data, studies are warranted to further investigate the use of 
      JAK inhibitors for treating AS.
CI  - (c) 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
FAU - Lee, Y H
AU  - Lee YH
AD  - Division of Rheumatology, Department of Internal Medicine, Korea University Anam 
      Hospital, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 
      02841, Seoul, Korea (Republic of). lyhcgh@korea.ac.kr.
FAU - Song, G G
AU  - Song GG
AD  - Division of Rheumatology, Department of Internal Medicine, Korea University Anam 
      Hospital, Korea University College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 
      02841, Seoul, Korea (Republic of).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
TT  - Januskinaseinhibitoren in der Behandlung der aktiven ankylosierenden Spondylitis: 
      Metaanalyse randomisierter kontrollierter Studien.
DEP - 20201218
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Janus Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Janus Kinase Inhibitors/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Spine
MH  - *Spondylarthritis
MH  - *Spondylitis, Ankylosing/diagnosis/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Ankylosing spondylitis
OT  - JAK inhibitor
OT  - Meta-analysis
OT  - Non-steroidal anti-inflammatory drugs
EDAT- 2020/12/20 06:00
MHDA- 2022/02/09 06:00
CRDT- 2020/12/19 05:29
PHST- 2020/11/29 00:00 [accepted]
PHST- 2020/12/20 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
PHST- 2020/12/19 05:29 [entrez]
AID - 10.1007/s00393-020-00948-3 [pii]
AID - 10.1007/s00393-020-00948-3 [doi]
PST - ppublish
SO  - Z Rheumatol. 2022 Feb;81(1):71-76. doi: 10.1007/s00393-020-00948-3. Epub 2020 Dec 
      18.